1
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): August 8, 1996
DURAMED PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-15242 11-2590026
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
7155 East Kemper Road, Cincinnati, Ohio 45249 (513) 731-9900
(Address and telephone number, including area code, of principal
executive offices)
2
INFORMATION TO BE INCLUDED IN THE REPORT
Items 1, 2, 3, 4, 6 and 8 are not applicable and are omitted from this Report.
Item 5. Other Events
The information set forth in the Proxy Statement/Prospectus dated
August 8, 1996 contained in the Company's Registration Statement
(No. 333-06901) on Form S-4, as amended, is incorporated herein by
reference.
Item 7. Financial Statements, Pro Forma Financial Information and
Exhibits.
(a) Financial Statements of Business Acquired.
Not Applicable
(b) Pro Forma Financial Information.
Not Applicable
(c) Exhibits.
The following exhibit is filed with this Report on Form 8-K:
Regulation S-K
Exhibit No. Exhibit
--------------- -------
99 Proxy Statement/Prospectus dated August 8, 1996
-2-
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: August 8, 1996 DURAMED PHARMACEUTICALS, INC.
By /s/ Timothy J. Holt
----------------------------------
Timothy J. Holt
Senior Vice President-Finance and
Administration
-3-